FDA Approves Ogsiveo for Desmoid Tumors

Approval marks first approved systemic treatment for the rare cancer
FDA Approves Ogsiveo for Desmoid Tumors
Adobe Stock

WEDNESDAY, Nov. 29, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.

The Fast Track and Breakthrough Therapy-designated approval was based on results from an international, multicenter trial in which 142 adult patients with progressing desmoid tumors not amenable to surgery were randomly assigned to receive 150 mg of Ogsiveo or placebo orally twice a day. 

Results from the trial showed clinically meaningful and statistically significant improvement in progression-free survival for Ogsiveo compared with placebo. There was also a statistically significant benefit seen for Ogsiveo in the objective response rate (41 versus 8 percent). Additional benefit was seen for patient-reported pain favoring the Ogsiveo arm.

"Desmoid tumors are rare tumors that can lead to severe pain and disability," Richard Pazdur, M.D., director of the FDA Oncology Center of Excellence, said in a statement. "Today's approval will offer the first approved treatment option for patients beyond surgery and radiation."

Approval of Ogsiveo was granted to SpringWorks Therapeutics Inc.

More Information

Related Stories

No stories found.